临床实践
Copyright ©The Author(s) 2023.
世界华人消化杂志. 2023-05-28; 31(10): 418-425
在线出版 2023-05-28. doi: 10.11569/wcjd.v31.i10.418
表1 3组一般资料比较
项目A组(n = 67)B组(n = 67)C组(n = 66)t/χ2P
性别(男/女)38/2940/2737/290.2060.902
年龄(岁)37-76(62.52±5.36)40-75(63.17±5.68)38-72(61.89±5.02)0.9480.389
术前病理分期1.1020.894
Ⅰ期15(22.39)13(19.40)13(19.70)
Ⅱ期34(50.75)32(47.76)30(45.45)
Ⅲ期18(26.87)22(32.84)23(34.85)
ASA分级0.5700.966
Ⅰ级12(17.91)10(14.93)10(15.15)
Ⅱ级34(50.75)33(49.25)35(53.03)
Ⅲ级21(31.34)24(35.82)21(31.82)
疾病类型0.7650.943
乙状结肠癌24(35.82)22(32.84)25(37.88)
横结肠癌20(29.85)19(28.36)20(30.30)
直肠癌23(34.33)26(38.81)21(31.82)
表2 对比3组生命体征(mean±SD)
项目组别T0T1T2T3
HR(次/min)A组/67例67.81±5.5669.03±4.8968.33±4.8971.92±5.01
B组/67例68.84±4.8780.25±4.0679.78±3.9172.24±4.88
C组/66例69.00±4.1190.67±5.6788.88±5.4372.86±5.12
F1.166322.688308.6100.606
P0.314<0.001<0.0010.547
MAP(mmHg)A组/67例82.57±4.5984.91±4.3783.62±4.6682.28±4.89
B组/67例81.99±5.1890.44±5.5988.55±3.9881.56±5.24
C组/66例83.33±4.11100.08±6.1698.44±5.0382.66±4.17
F1.388133.209180.7010.906
P0.252<0.001<0.0010.406
SaO2(%)A组/67例97.54±4.3196.64±4.6595.88±4.8796.31±4.55
B组/67例96.88±5.2297.01±4.0196.48±4.0395.99±5.01
C组/66例97.56±4.3695.88±5.0397.11±3.7696.58±4.95
F0.4631.0511.3930.248
P0.6300.3520.2510.781
表3 对比3组镇痛效果(mean±SD)
组别VAS评分(分)
术后24 h镇痛泵按压次数(次)补救性镇痛次数(次)
术后6 h12 h24 h
A组/67例3.02±0.462.11±0.331.65±0.313.20±0.332.60±0.29
B组/67例3.48±0.552.87±0.391.93±0.353.89±0.413.01±0.34
C组/66例4.26±0.593.39±0.462.24±0.384.55±0.553.26±0.43
F90.907175.40447.902157.34457.797
P<0.001<0.001<0.001<0.001<0.001
表4 对比3组免疫细胞因子(mean±SD)
组别TNF-α(ng/L)
IL-2(pg/mL)
IL-10(pg/mL)
术前术后12 h24 h术前术后12 h24 h术前术后12 h24 h
A组/67例20.22±3.8823.38±4.1220.18±3.7810.73±3.218.18±1.6710.68±3.198.38±1.4310.17±1.878.59±1.36
B组/67例18.91±4.3627.75±4.7323.81±4.1211.05±1.986.46±1.388.99±1.567.96±1.8814.49±2.2512.24±1.88
C组/66例19.34±4.0133.18±4.9825.76±4.8911.89±3.084.39±1.017.54±1.388.17±1.5117.78±3.1714.18±2.13
F1.78674.98129.0863.018125.39133.8551.127156.765162.560
P0.170<0.001<0.0010.051<0.001<0.0010.326<0.001<0.001
表5 对比3组血清神经递质(mean±SD)
组别S100B
NSE(ng/mL)
BDNF(pg/mL)
术前术后12 h24 h术前术后12 h24 h术前术后12 h24 h
A组/67例1.30±0.451.56±0.511.33±0.416.80±1.419.31±1.986.85±1.3430.83±4.3726.26±2.8830.37±4.38
B组/67例1.41±0.371.87±0.671.38±0.396.77±1.2211.48±2.236.80±1.2732.24±3.0123.38±1.3431.89±4.47
C组/66例1.35±0.412.46±0.851.40±0.446.91±1.1813.38±2.876.86±1.3131.78±3.3920.21±1.1131.31±4.62
F1.20129.1670.5060.22248.4230.0402.618160.7671.955
P0.303<0.0010.6040.801<0.0010.9600.076<0.0010.144
表6 对比3组不良反应n(%)
组别呛咳心动过缓躁动寒战恶心呕吐总发生率
A组/67例0(0.00)1(1.49)1(1.49)1(1.49)2(2.99)5(7.46)
B组/67例1(1.49)1(1.49)1(1.49)2(2.99)2(2.99)7(10.45)
C组/66例0(0.00)0(0.00)5(7.58)2(3.03)3(4.55)10(15.15)
χ22.039
P0.361

引文著录: 羊瑛, 冯定祥, 王莹. 结直肠癌根治术中右美托咪定结合超声引导的腹横筋膜全麻阻滞临床观察. 世界华人消化杂志 2023; 31(10): 418-425